Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)

NCT01819779 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male Subjects

Interventions

DRUG: Exforge tab. 10/160mg
DRUG: Lodivixx tab. 5/160mg

Sponsor

Hanlim Pharm. Co., Ltd.